ATYR 2810
Alternative Names: ATYR-2810Latest Information Update: 20 Apr 2023
At a glance
- Originator aTyr Pharma; Pangu BioPharma
- Developer aTyr Pharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Neuropilin-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 17 Apr 2023 Pharmacodynamics data from a preclinical trial in Soli tumours released by aTyr Pharma
- 14 Apr 2023 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 11 Apr 2022 Pharmacodynamics data from a preclinical trial in Cancer presented at the at the American Association for Cancer Research Annual Meeting 2022 (AACR-2022)